.cls-1{fill:#f55014;}.cls-2{fill:#776e64;} Transforming life for patients with Parkinson’s disease Share this: Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls. Two clinical phase II candidates Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more > Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more > Proprietary technology platform The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more > Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease. Read more here > Latest press release IRLAB publishes interim report for July 1 – September 30, 2021 November 10, 2021 Regulatory IRLAB today published its interim report for the third quarter 2021 (July 1 – September 30, 2021) Read More > All press releases > Latest presentation Earnings call Q3 November 10, 2021 Telco in connection with publication of quarterly report for the thrid quarter 2021 The presentation is available here (held in Swedish): https://tv.streamfabriken.com/irlab-q3-2021 To download the presentation as a pdf (in English), click here: IRLAB Q3 2021 presentation For more information Åsa Hillsten, Head of IR & Corporate Communications Telephone: +46 700 81 81 17 E-mail: […] Read More > All presentations > IRLAB A 48.45 SEK (-1.1%) About the share > Upcoming events February 23, 2022 Year-end Report, 2021 Subscribe Get immediate updates, subscribe to our press releases. Subscribe By subscribing, you accept that IRLAB stores and handles your personal data to provide relevant information about the company. Read more in our Integrity policy. You can, at any time, unsubscribe by clicking the link in the distributed email. IRLAB Therapeutics AB (publ) Arvid Wallgrens Backe 20 413 46 Göteborg +46 31 757 38 00 Copyright © 2021 IRLAB Integrity policy

.cls-1{fill:#f55014;}.cls-2{fill:#776e64;} Hem>Investors>The share>Analysts Analysts Share this: Edison Investment Research Name: Dr Susie Jana Name: Dr John Priestner Subscribe for updates > Redeye Name: Anders Hedlund Email: anders.hedlund@redeye.se Read more here: https://www.redeye.se/company/irlab-therapeutics IRLAB Therapeutics AB (publ) Arvid Wallgrens Backe 20 413 46 Göteborg +46 31 757 38 00 Copyright © 2021 IRLAB Integrity policy